Table 3.
Pharmacokinetic parameter estimates following T- and R-state PolybHb transfusion.
| Estimate | Total PolybHb | PolybHb (Fe2+) | PolybHb (Fe3+) |
|---|---|---|---|
| T-State PolybHb | |||
| Dose (mg) | 506.4 ± 0.42 | 489.1 ± 0.36 | 1.3 ± 0.10 |
| Cmax (mg•mL-1) | 14.4 ± 0.44 | 12.0 ± 0.43 | 3.27 ± 0.32 |
| Tmax (h) | 0.17 | 0.17 | 8.0 ± 2.3 |
| AUC0-tlast (mg•h•mL-1) | 214.9 ± 9.91 | 124.7 ± 6.52 | 90.1 ± 5.78 (41.9% total) |
| AUC0-∞ (mg•h•mL-1) | 252.4 ± 34.1 | 139.4 ± 14.5 | 113.0 ± 20.9 (44.3% total) |
| Cl (mL•h-1) | 2.1 ± 0.24 | 3.6 ± 0.36 | |
| Vdss (mL) | 42.98 ± 5.5 | 61.3 ± 7.2 | |
| t1/2 (h) | 11.1 ± 0.22 | 6.85 ± 0.07 | |
| MRTi.v.(h) | 22.15 ± 5.9 | 17.91 ± 4.0 | |
| In vitro kox (min-1) | 1.23•10-3 ± 3.37•10-5 | ||
| R-State PolybHb | |||
| Dose (mg) | 508.5 ± 0.77 | 491.1 ± 1.0 | 1.0 ± 0.03 |
| Cmax (mg•mL-1) | 13.1 ± 0.50 | 10.4 ± 0.70 | 4.57 ± 0.31† |
| Tmax (h) | 0.17 | 0.17 | 4.0 ± 2.0† |
| AUC0-tlast (mg•h•mL-1) | 127.4 ± 11.2† | 75.4 ± 12.1† | 51.9 ± 5.71† (40.5% total) |
| AUC0-∞ (mg•h•mL-1) | 158.5 ± 25† | 94.8 ± 24.1† | 63.7 ± 8.3 † (41.5% total) |
| Cl (mL•h-1) | 3.8 ± 0.40† | 7.0 ± 1.2† | |
| Vdss (mL) | 44.3 ± 0.67 | 69.4 ± 1.0 | |
| t1/2 (h) | 7.31 ± 0.53† | 5.60 ± 1.3 | |
| MRTi.v.(h) | 13.6 ± 1.9† | 13.3 ± 3.2 | |
| In vitro kox (min-1) | 9.0•10-4 ± 3.34•10-5* |
†
Significant difference between T- and R-state PolybHb parameter estimates (p<0.05)
*
= Significant difference between T- and R-state PolybHb in vitro oxidation (p<0.05)